Navigation Links
AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
Date:8/17/2012

LOS ALTOS, Calif., Aug. 17, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.

(Photo: http://photos.prnewswire.com/prnh/20120817/CG59299)

Our antibody demonstrated a great safety profile in preclinical safety and phase 1 clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase 1 psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current Phase 2 clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial. The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.

About AbGenomics (www.abgenomics.com)

AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. Currently, the company has two therapeutic candidates in clinical trials. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.

Media Contact: RUTH LI ABGENOMICS INTERNATIONAL INC., 6509889912, ABG@ABGENOMICS.COM

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AbGenomics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Chindex International, Inc. to Report First Quarter 2012 Financial Results
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Bacterin International Signs Its Third National GPO Contract with Novation
11. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... 20, 2017  Prime Therapeutics LLC (Prime) released this statement ... following today,s Institute for Clinical and Economic Review,s (ICER) ... effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime ... at the meeting. ... benefit to the use of abuse-deterrent formulations (ADF) in opioids ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... weeks Nature’s Tears® EyeMist®, the signature product of her research center at Bio-Logic ... the world’s largest population and the greatest number of sufferers of blindness. “We ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata ... and boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device ...
Breaking Medicine News(10 mins):